drugset / Trial / NCT07057427
Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this study is to evaluate the efficacy of nab-paclitaxel (on days 1 and 8 of a 21-day cycle) compared to the standard regimen of docetaxel plus carboplatin, both combined with trastuzumab and pertuzumab, as neoadjuvant therapies for HER2-positive breast cancer.
Timeline
- Start
- 2025-06-24
- Primary completion
- 2028-06-30
- Completion
- 2029-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Carboplatin | Small molecule | 6 unknown | — |
| Comparator | Docetaxel | Small molecule | 75 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | — | — |
| Background | Pertuzumab | Monoclonal antibody | 420 mg/kg | Intravenous |
| Background | Pertuzumab | Monoclonal antibody | 600 mg | Intravenous |
| Background | Trastuzumab | Monoclonal antibody | 6 mg/kg | Intravenous |
| Background | Trastuzumab | Monoclonal antibody | 600 mg | Intravenous |